Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. OBJECTIVE: This trial assessed card...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA
Prif Awduron: Rosenstock, Julio, Kahn, Steven E., Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A., Woerle, Hans J., Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K., Marx, Nikolaus
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2019
Pynciau:
Original Investigation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6763993/
https://ncbi.nlm.nih.gov/pubmed/31536101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.13772
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg